Skip to main content
. 2020 Nov 1;27(Suppl 3):S152–S164. doi: 10.3747/co.27.7315

TABLE I.

Current approval status of immunotherapy in hepatocellular carcinoma

Agent Type Line U.S. FDA EMA
Nivolumab Anti–PD-1 2 Yes (Sep 2017) No
Pembrolizumab Anti–PD-1 2 Yes (Nov 2018) No
Atezolizumab Anti–PD-L1 1 Yes (May 2020)a Yes (Nov 2020)
Ipilimumab Anti–CTLA-4 2 Yes (Mar 2020)b No
a

In combination with bevacizumab.

b

In combination with nivolumab.

FDA = Food and Drug Administration; EMA = European Medicines Agency.